89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases... Show more
ETNB moved below its 50-day moving average on July 25, 2025 date and that indicates a change from an upward trend to a downward trend. In of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for ETNB moved out of overbought territory on July 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ETNB as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ETNB turned negative on July 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ETNB broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for ETNB moved above the 200-day moving average on June 20, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ETNB advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 183 cases where ETNB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.312) is normal, around the industry mean (18.053). P/E Ratio (0.000) is within average values for comparable stocks, (59.920). ETNB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.580). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (280.104).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ETNB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ETNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
WLGAX | 38.66 | N/A | N/A |
Macquarie Large Cap Growth Fund A | |||
LADCX | 9.76 | N/A | N/A |
Lord Abbett Developing Growth C | |||
CDCRX | 11.70 | N/A | N/A |
Copeland Dividend Growth Fund Class C | |||
AWIIX | 16.11 | N/A | N/A |
CIBC Atlas Income Opportunities Instl | |||
GVIZX | 12.44 | N/A | N/A |
GuideStone Funds Value Equity Index Inv |
A.I.dvisor indicates that over the last year, ETNB has been loosely correlated with AKRO. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ETNB jumps, then AKRO could also see price increases.
Ticker / NAME | Correlation To ETNB | 1D Price Change % | ||
---|---|---|---|---|
ETNB | 100% | -0.99% | ||
AKRO - ETNB | 60% Loosely correlated | -2.53% | ||
IDYA - ETNB | 54% Loosely correlated | +5.08% | ||
BEAM - ETNB | 51% Loosely correlated | -5.46% | ||
DNLI - ETNB | 50% Loosely correlated | -1.11% | ||
SNDX - ETNB | 50% Loosely correlated | -2.25% | ||
More |